Organogenesis Holdings Inc.
A regenerative-medicine company that grows living skin and tissue grafts to help wounds heal. Its best-known product, Apligraf, was the first living cell-based skin substitute approved by the U.S. Food and Drug Administration, and its PuraPly line treats chronic wounds like diabetic ulcers. Founded in 1985 in Cambridge, Massachusetts, the company's name reflects its mission of growing organs and tissues in the lab.
Sold 500.0K
Granted 188.9K
Granted 49.1K
Granted 43.2K
Granted 48.8K
Granted 44.0K
Granted 48.8K · Bought 5.0K
Granted 16.5K
Granted 48.8K
Granted 48.8K
Granted 48.8K
Granted 48.8K
Granted 11.3K
Granted 48.8K · Bought 10.0K
Granted 48.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Nussdorf Glenn HDirector · 4 transactions | — | 22.74M | — | — | 500.0K |
| Gillheeney Gary S.President and CEO, Director · 6 transactions | +23% | 4.32M | 188.9K | — | — |
| Bilbo PatrickChief Operating Officer · 6 transactions | +18.9% | 1.13M | 49.1K | — | — |
| Freedman LoriChief Admin. and Legal Officer · 6 transactions | +20.9% | 1.02M | 43.2K | — | — |
| Grow BrianChief Commercial Officer · 6 transactions | +35.1% | 911.6K | 48.8K | — | — |
| Francisco DavidChief Financial Officer · 6 transactions | +33.4% | 746.0K | 44.0K | — | — |
| Leibowitz Arthur SDirector · 2 transactions | +22.7% | 291.0K | 48.8K | 5.0K | — |
| Cavorsi RobertVice President, Strategy · 6 transactions | +45.7% | 275.5K | 16.5K | — | — |
| Duraibabu PrathyushaDirector · 1 transaction | +24.6% | 247.0K | 48.8K | — | — |
| Giacomin Jon LDirector · 1 transaction | +25.4% | 241.0K | 48.8K | — | — |
| Korfin Michele IleneDirector · 1 transaction | +25.7% | 239.1K | 48.8K | — | — |
| Quintero GilbertoDirector · 1 transaction | +25.7% | 239.1K | 48.8K | — | — |
| Montecalvo Antonio S.Vice President, Health Policy · 6 transactions | +16.9% | 230.0K | 11.3K | — | — |
| Driscoll Michael JosephDirector · 2 transactions | +35.3% | 225.7K | 48.8K | 10.0K | — |
| Lustig GarrettDirector · 1 transaction | +63.5% | 125.7K | 48.8K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -485.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.